(NASDAQ: ABVX) Abivax Sa's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.25%.
Abivax Sa's revenue in 2026 is N/A.On average, 8 Wall Street analysts forecast ABVX's revenue for 2026 to be $593,985,419, with the lowest ABVX revenue forecast at $285,941,648, and the highest ABVX revenue forecast at $949,734,760. On average, 6 Wall Street analysts forecast ABVX's revenue for 2027 to be $18,197,414,022, with the lowest ABVX revenue forecast at $5,776,021,293, and the highest ABVX revenue forecast at $45,993,568,218.
In 2028, ABVX is forecast to generate $32,492,308,101 in revenue, with the lowest revenue forecast at $18,238,262,829 and the highest revenue forecast at $66,195,491,549.